194 related articles for article (PubMed ID: 32744930)
1. Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011-30.
Sim SY; Watts E; Constenla D; Brenzel L; Patenaude BN
Health Aff (Millwood); 2020 Aug; 39(8):1343-1353. PubMed ID: 32744930
[TBL] [Abstract][Full Text] [Related]
2. Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20.
Ozawa S; Clark S; Portnoy A; Grewal S; Brenzel L; Walker DG
Health Aff (Millwood); 2016 Feb; 35(2):199-207. PubMed ID: 26858370
[TBL] [Abstract][Full Text] [Related]
3. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
[TBL] [Abstract][Full Text] [Related]
4. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
[TBL] [Abstract][Full Text] [Related]
5. Trends in vaccine investment in middle income countries.
Onishchenko K; Hill S; Wasserman M; Jones C; Moffatt M; Ruff L; Pugh SJ
Hum Vaccin Immunother; 2019; 15(10):2378-2385. PubMed ID: 30843757
[TBL] [Abstract][Full Text] [Related]
6. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
[TBL] [Abstract][Full Text] [Related]
7. Return on Investment of 10-Valent Pneumococcal Conjugate Vaccine in Ecuador From 2010 to 2030.
Jimbo-Sotomayor R; Watts E; Armijos L; Sriudomporn S; Sánchez X; Echeverria A; Whittembury A; Patenaude B
Value Health Reg Issues; 2022 Sep; 31():148-154. PubMed ID: 35753214
[TBL] [Abstract][Full Text] [Related]
8. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of the costs and effectiveness of interventions to increase infant vaccination coverage in low- and middle-income countries.
Munk C; Portnoy A; Suharlim C; Clarke-Deelder E; Brenzel L; Resch SC; Menzies NA
BMC Health Serv Res; 2019 Oct; 19(1):741. PubMed ID: 31640687
[TBL] [Abstract][Full Text] [Related]
10. Influenza vaccine programs for children in low- and middle-income countries: current status and way forward.
Ortiz JR; Neuzil KM
Expert Rev Vaccines; 2019 Jul; 18(7):711-724. PubMed ID: 31226895
[No Abstract] [Full Text] [Related]
11. Funding gap for immunization across 94 low- and middle-income countries.
Ozawa S; Grewal S; Portnoy A; Sinha A; Arilotta R; Stack ML; Brenzel L
Vaccine; 2016 Dec; 34(50):6408-6416. PubMed ID: 28029541
[TBL] [Abstract][Full Text] [Related]
12. Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.
Ward ZJ; Scott AM; Hricak H; Atun R
Lancet Oncol; 2021 Mar; 22(3):341-350. PubMed ID: 33662286
[TBL] [Abstract][Full Text] [Related]
13. An analysis of government immunization program expenditures in lower and lower middle income countries 2006-12.
Nader AA; de Quadros C; Politi C; McQuestion M
Health Policy Plan; 2015 Apr; 30(3):281-8. PubMed ID: 24561878
[TBL] [Abstract][Full Text] [Related]
14. Public health impact and return on investment of the pediatric immunization program in Poland.
Mellott CE; Jaworski R; Carrico J; Talbird SE; Dobrowolska I; Golicki D; Bencina G; Clinkscales M; Karamousouli E; Eiden AL; Sabale U
Expert Rev Vaccines; 2023; 22(1):1114-1125. PubMed ID: 37909887
[TBL] [Abstract][Full Text] [Related]
15. Economic Benefit of Hand Surgical Efforts in Low- and Middle-Income Countries: A Cost-Benefit Analysis.
Billig JI; Nasser JS; Sue GR; Chang J; Chung KC
Plast Reconstr Surg; 2020 Feb; 145(2):471-481. PubMed ID: 31985644
[TBL] [Abstract][Full Text] [Related]
16. Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.
Mauskopf J; Standaert B; Connolly MP; Culyer AJ; Garrison LP; Hutubessy R; Jit M; Pitman R; Revill P; Severens JL
Value Health; 2018 Oct; 21(10):1133-1149. PubMed ID: 30314613
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review.
Ozawa S; Mirelman A; Stack ML; Walker DG; Levine OS
Vaccine; 2012 Dec; 31(1):96-108. PubMed ID: 23142307
[TBL] [Abstract][Full Text] [Related]
18. Value and effectiveness of National Immunization Technical Advisory Groups in low- and middle-income countries: a qualitative study of global and national perspectives.
Bell S; Blanchard L; Walls H; Mounier-Jack S; Howard N
Health Policy Plan; 2019 May; 34(4):271-281. PubMed ID: 31074778
[TBL] [Abstract][Full Text] [Related]
19. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
20. The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.
Hutubessy R; Lauer JA; Giersing B; Sim SY; Jit M; Kaslow D; Botwright S
BMC Med; 2023 Jul; 21(1):229. PubMed ID: 37400797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
